Table 2.

Neutrophil-to-lymphocyte ratio at univariate analysis

	All sample (n = 1,169)	Lung (n = 635)	RCC (n = 200)	Melanoma (n = 150)
	HR (95% CI); p value	HR (95% CI); p value	HR (95% CI); p value	HR (95% CI); p value
NLR (continuous; 10-unit difference)	1.21 (1.12–1.31); p < 0.001, c-index = 0.595	1.17 (1.06–1.31); p = 0.003, c-index = 0.583	1.80 (0.99–3.30); p = 0.055, c-index = 0.599	2.43 (1.00–5.90); p = 0.050, c-index = 0.557
NLR
<4.0	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
≥4.0	1.68 (1.41–2.00); p < 0.001, c-index = 0.566	1.42 (1.14–1.78); p = 0.002, c-index = 0.549	1.65 (1.01–2.70); p = 0.045, c-index = 0.556	1.52 (0.78–2.95); p = 0.22, c-index = 0.546
NLR
<3.4	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
≥3.4	1.67 (1.40–2.00); p < 0.001, c-index = 0.569	1.54 (1.22–1.93); p < 0.001, c-index = 0.561	1.58 (0.98–2.53); p = 0.059, c-index = 0.555	1.18 (0.62–2.23); p = 0.62, c-index = 0.522
dNLR
≤3	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
>3	1.75 (1.40–2.17); p < 0.001, c-index = 0.544	1.67 (1.28–2.19); p < 0.001, c-index = 0.547	1.85 (0.94–3.62); p = 0.073 c-index = 0.537	3.66 (1.69–7.92); p = 0.001, c-index = 0.565

95% CI, 95% confidence interval; HR, hazard ratio; dNLR, derived neutrophil-to-lymphocyte ratio; n, number; NLR, neutrophil-to-lymphocyte ratio; RCC, renal cell carcinoma.